HC Wainwright & Co. Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and set a price target of $16.
August 12, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Summit Therapeutics with a Buy rating and set a price target of $16.
The initiation of coverage with a Buy rating and a price target of $16 by a reputable analyst firm like HC Wainwright & Co. is likely to positively impact the stock price of Summit Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100